Molecular subtyping based on immune cell marker genes predicts prognosis and therapeutic response in patients with lung adenocarcinoma
Zi-Tao Liu(Kunming Medical University), Tingdong Yu(Kunming Medical University), Long Chen(Kunming Medical University), Xi Wang(Westlake University), Zixuan Li(Tibet University), Yutian Wang(Yunnan University), Guangqiang Zhao(Kunming Medical University), Yunchao Huang(North China University of Water Resources and Electric Power), Chenghong Zheng(Kunming Medical University), Shou-Zhuo Li(Kunming Medical University), Jun Liao(Kunming Medical University), Yujie Lei(Kunming Medical University), Junting Shen(Kunming Medical University)
Cited by 4
Related Papers
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Clinical characteristics and medical service utilization of lung cancer in China, 2005–2014: Overall design and results from a multicenter retrospective epidemiologic survey
|Lung Cancer|2018|134